Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000232385 | SCV000291062 | pathogenic | Familial cancer of breast | 2017-05-08 | criteria provided, single submitter | clinical testing | This sequence change inserts 1 nucleotide in exon 7 of the BRIP1 mRNA (c.890_891insT), causing a frameshift at codon 297. This creates a premature translational stop signal (p.Lys297Asnfs*22) and is expected to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, loss-of-function variants in BRIP1 are known to be pathogenic (PMID: 16116423, 17033622, 21964575). For these reasons, this variant has been classified as Pathogenic. |
Labcorp Genetics |
RCV001381186 | SCV001579475 | pathogenic | Familial cancer of breast; Fanconi anemia complementation group J | 2017-05-02 | criteria provided, single submitter | clinical testing | While this particular variant has not been reported in the literature, loss-of-function variants in BRIP1 are known to be pathogenic (PMID: 16116423, 17033622, 21964575). This sequence change inserts 1 nucleotide in exon 7 of the BRIP1 mRNA (c.890_891insT), causing a frameshift at codon 297. This creates a premature translational stop signal (p.Lys297Asnfs*22) and is expected to result in an absent or disrupted protein product. For these reasons, this variant has been classified as Pathogenic. |
Myriad Genetics, |
RCV000232385 | SCV004043581 | pathogenic | Familial cancer of breast | 2023-06-01 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. |